• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病简史:一个共同名称下的多重含义。

A brief history of "Alzheimer disease": Multiple meanings separated by a common name.

机构信息

From the Departments of Neurology (D.S.K., R.C.P.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN.

出版信息

Neurology. 2019 May 28;92(22):1053-1059. doi: 10.1212/WNL.0000000000007583. Epub 2019 Apr 26.

DOI:10.1212/WNL.0000000000007583
PMID:31028129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6556090/
Abstract

The field of Alzheimer disease (AD) has a nosologic problem: The diagnostic label "Alzheimer disease" has several distinctive meanings. The term probable AD was introduced in 1984 to designate a clinically diagnosed acquired and progressive amnestic dementia for which there was no evidence for another etiology. Probable AD represented a clinicopathologic entity that assumed a specific and sensitive linkage between amnestic dementia and the neuropathology of β-amyloid-containing neuritic plaques and tau-containing neurofibrillary tangles. The clinicopathologic model represented by probable AD was adapted in abbreviated form for population-based studies and general clinical practice, although the uncertainty connoted by "probable" was often overlooked. Representing the growing public awareness of later life cognitive impairment, a vernacular meaning of AD arose out of the clinicopathologic model in which AD represented all dementia not due to another clinically apparent cause. In contrast, by the 1990s, neuropathologists settled on a definition of AD based entirely on a sufficient burden of neuritic plaques and neurofibrillary tangles at postmortem examination, regardless of antemortem clinical status. In the last decade, the availability of fluid and imaging biomarkers that measure β-amyloid and tau abnormalities has enabled antemortem pathobiological diagnoses, highlighting the divide between the clinicopathologic model, the vernacular usage, and the pathobiological models. Each definition has value. However, the meanings of AD as defined by each of these models are not interchangeable. The pathobiological one is the only one that is unambiguous.

摘要

阿尔茨海默病(AD)领域存在一个命名问题:“阿尔茨海默病”这一诊断标签有几种不同的含义。“可能的阿尔茨海默病”一词于 1984 年引入,用于指代一种临床上诊断为获得性、进行性遗忘性痴呆,且无其他病因证据的疾病。可能的阿尔茨海默病代表了一种临床病理实体,假设遗忘性痴呆与β-淀粉样蛋白含神经原纤维缠结和 tau 含神经原纤维缠结的神经病理学之间存在特定且敏感的联系。可能的阿尔茨海默病所代表的临床病理模型以缩写形式被应用于基于人群的研究和一般临床实践中,尽管“可能的”所隐含的不确定性常常被忽视。随着公众对晚年认知障碍的认识不断提高,阿尔茨海默病的一个通俗含义从临床病理模型中产生,即阿尔茨海默病代表了所有非因其他明显临床原因引起的痴呆。相比之下,到 20 世纪 90 年代,神经病理学家基于死后检查中存在足够数量的神经原纤维缠结和神经原纤维缠结,而不管生前的临床状况如何,对阿尔茨海默病定义达成了共识。在过去的十年中,可测量β-淀粉样蛋白和 tau 异常的液体和成像生物标志物的出现,使得生前进行病理生物学诊断成为可能,这凸显了临床病理模型、通俗用法和病理生物学模型之间的分歧。每种定义都有其价值。然而,这些模型中定义的阿尔茨海默病的含义并不相互替代。病理生物学模型是唯一明确的模型。

相似文献

1
A brief history of "Alzheimer disease": Multiple meanings separated by a common name.阿尔茨海默病简史:一个共同名称下的多重含义。
Neurology. 2019 May 28;92(22):1053-1059. doi: 10.1212/WNL.0000000000007583. Epub 2019 Apr 26.
2
How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture.我们能多早诊断阿尔茨海默病(以及这是否足够)?2017 年瓦滕伯格讲座。
Neurology. 2018 Aug 28;91(9):395-402. doi: 10.1212/WNL.0000000000006088. Epub 2018 Aug 8.
3
What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries.什么是阿尔茨海默病?20 世纪和 21 世纪的分类学观点分析。
Eur J Neurol. 2024 Nov;31(11):e16302. doi: 10.1111/ene.16302. Epub 2024 Apr 15.
4
Neuropathological assessment of the Alzheimer spectrum.阿尔茨海默病谱系的神经病理学评估。
J Neural Transm (Vienna). 2020 Sep;127(9):1229-1256. doi: 10.1007/s00702-020-02232-9. Epub 2020 Aug 1.
5
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
6
Biomarkers of Alzheimer disease.阿尔茨海默病的生物标志物
Arch Neurol. 1999 Mar;56(3):281-3. doi: 10.1001/archneur.56.3.281.
7
Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.用有轻度至中度阿尔茨海默病和最小β-淀粉样肽斑块的临床诊断来描述载脂蛋白 E ε4 携带者和非携带者。
JAMA Neurol. 2015 Oct;72(10):1124-31. doi: 10.1001/jamaneurol.2015.1721.
8
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.脑脊液β淀粉样蛋白42和tau蛋白作为大脑中阿尔茨海默病型病理变化的生物标志物。
Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.
9
Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects.阿尔茨海默病患者生前海马体体积与死后神经病理学之间的相关性。
Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):190-5.
10
Amyloid beta protein as a marker or risk factor of Alzheimer's disease.淀粉样β蛋白作为阿尔茨海默病的标志物或风险因素。
Curr Alzheimer Res. 2007 Sep;4(4):359-63. doi: 10.2174/156720507781788891.

引用本文的文献

1
The Role of Oxidative Stress in the Relationship Between Periodontitis and Alzheimer's Disease: A Review of the Literature.氧化应激在牙周炎与阿尔茨海默病关系中的作用:文献综述
J Pers Med. 2025 Aug 18;15(8):384. doi: 10.3390/jpm15080384.
2
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.血浆生物标志物可识别无痴呆症的基于人群队列中的脑淀粉样蛋白、tau蛋白和神经退行性变异常。
Alzheimers Res Ther. 2025 Jul 25;17(1):173. doi: 10.1186/s13195-025-01803-w.
3
Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease.用于阿尔茨海默病早期检测与管理的分子成像进展
Cureus. 2025 Apr 28;17(4):e83127. doi: 10.7759/cureus.83127. eCollection 2025 Apr.
4
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.血浆生物标志物可在无痴呆的基于人群的队列中识别脑淀粉样蛋白、tau蛋白和神经退行性变异常。
medRxiv. 2025 Apr 28:2025.04.27.25326360. doi: 10.1101/2025.04.27.25326360.
5
The role of quantitative EEG biomarkers in Alzheimer's disease and mild cognitive impairment: applications and insights.定量脑电图生物标志物在阿尔茨海默病和轻度认知障碍中的作用:应用与见解。
Front Aging Neurosci. 2025 Apr 23;17:1522552. doi: 10.3389/fnagi.2025.1522552. eCollection 2025.
6
Retinal vascular changes are associated with PET-based biomarkers of Alzheimer's disease: A pilot study.视网膜血管变化与基于正电子发射断层扫描的阿尔茨海默病生物标志物相关:一项初步研究。
J Alzheimers Dis Rep. 2024 Dec 8;8(1):1639-1648. doi: 10.1177/25424823241300416. eCollection 2024.
7
[Preface for Special Issue on Alzheimer's Disease: New Diagnostic Criteria, Treatment, and the Role of Neuroimaging].[阿尔茨海默病特刊前言:新诊断标准、治疗及神经影像学的作用]
J Korean Soc Radiol. 2025 Jan;86(1):4-5. doi: 10.3348/jksr.2025.0005. Epub 2025 Jan 23.
8
Nasal lymphatic obstruction of CSF drainage as a possible cause of Alzheimer's disease and dementia.脑脊液引流的鼻淋巴阻塞可能是阿尔茨海默病和痴呆症的一个病因。
Front Aging Neurosci. 2024 Oct 21;16:1482255. doi: 10.3389/fnagi.2024.1482255. eCollection 2024.
9
New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS.在临床环境中预测迟发性非典型性溶血尿毒综合征(LATE-NC)的新标准:可能/疑似迟发性非典型性溶血尿毒综合征和晚期非典型性溶血尿毒综合征。
J Neuropathol Exp Neurol. 2025 Jan 1;84(1):2-7. doi: 10.1093/jnen/nlae113.
10
Ex vivo propagation of synaptically-evoked cortical depolarizations in a mouse model of Alzheimer's disease at 20 Hz, 40 Hz, or 83 Hz.在阿尔茨海默病小鼠模型中,以 20 Hz、40 Hz 或 83 Hz 的频率进行突触诱发皮质去极化的体外传播。
Sci Rep. 2024 Oct 8;14(1):23365. doi: 10.1038/s41598-024-74262-2.

本文引用的文献

1
Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study.评估 TDP-43 蛋白病和海马硬化与 APOE ε4 单倍型状态的关系:一项基于社区的队列研究。
Lancet Neurol. 2018 Sep;17(9):773-781. doi: 10.1016/S1474-4422(18)30251-5. Epub 2018 Aug 6.
2
How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture.我们能多早诊断阿尔茨海默病(以及这是否足够)?2017 年瓦滕伯格讲座。
Neurology. 2018 Aug 28;91(9):395-402. doi: 10.1212/WNL.0000000000006088. Epub 2018 Aug 8.
3
Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.使用 18F-AV1451 正电子发射断层扫描成像评估皮质下血管性认知障碍的程度和 tau 的作用。
JAMA Neurol. 2018 Aug 1;75(8):999-1007. doi: 10.1001/jamaneurol.2018.0975.
4
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架:迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
5
FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.正电子发射断层扫描(FDG-PET)在 tau 阴性遗忘型痴呆中的表现类似于经尸检证实的海马硬化症。
Brain. 2018 Apr 1;141(4):1201-1217. doi: 10.1093/brain/awy049.
6
Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease.比较 F-AV-1451 与 CSF t-tau 和 p-tau 对阿尔茨海默病的诊断价值。
Neurology. 2018 Jan 30;90(5):e388-e395. doi: 10.1212/WNL.0000000000004887. Epub 2018 Jan 10.
7
Associations between [F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample.在临床样本中,[F]AV1451 tau PET 与 CSF 标志物 tau 病理之间的关联。
Neurology. 2018 Jan 23;90(4):e282-e290. doi: 10.1212/WNL.0000000000004860. Epub 2017 Dec 27.
8
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States.预测美国临床前期和临床阿尔茨海默病的流行情况。
Alzheimers Dement. 2018 Feb;14(2):121-129. doi: 10.1016/j.jalz.2017.10.009. Epub 2017 Dec 7.
9
Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.不同淀粉样蛋白免疫测定法与视觉淀粉样蛋白正电子发射断层扫描评估之间的一致性
JAMA Neurol. 2017 Dec 1;74(12):1492-1501. doi: 10.1001/jamaneurol.2017.2814.
10
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.神经退行性痴呆的脑脊液和血液生物标志物:世界生物精神病学学会联合会精神病学生物标志物工作组的共识更新。
World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27.